# US 2012/0252888 A1 · Compositions and Methods for Treating Neurologic Disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252888 A1
- Document ID: US20120252888A1
- Status: Published application
- Kind: A1
- Application number: 13/431,429
- Filed: 2012-03-27
- Published: 2012-10-04
- Earliest claimed: 2011-03-29
- Assignees: Palupa Medical Ltd.
- Inventors: Marios Pantzaris; Ioannis Patrikios; Georgios Loukaidis
- Web page: https://patentgrep.com/patent/US20120252888A1

## CPC

- A61K 31/015: carbocyclic
- A23L 33/12: Fatty acids or derivatives thereof
- A61K 9/0095: {Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches (A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 9/107: Emulsions {; Emulsion preconcentrates; Micelles (composition of emulsions A61K47/00)}
- A61K 31/201: having one or two double bonds, e.g. oleic, linoleic acids
- A61K 31/202: having three or more double bonds, e.g. linolenic (eicosanoids, e.g. leukotrienes A61K31/557)
- A61K 31/203: Retinoic acids {; Salts thereof}
- A61K 31/355: Tocopherols, e.g. vitamin E
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- A61K 2300/00: Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION

## Abstract

The present invention relates to compositions comprising DHA, EPA, LA and GLA. The compositions may further comprise other omega-3 PUFAs, MUFAs, SFAs, gamma tocopherol, Vitamin A and Vitamin B. The compositions are useful for treating neurologic disorders. The compositions are administered chronically for the prevention and/or treatment of multiple sclerosis (MS) and other degenerative diseases.

## Claims

### Claim 1

A liquid oral pharmaceutical composition, comprising
a long chain polyunsaturated fatty acid (PUFA) fraction, comprising eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), linoleic acid (LA) and gamma linolenic acid (GLA);
one or more other omega-3 PUFAs; and
one or more monounsaturated fatty acid (MUFA).

### Claim 2 (depends on 1)

The composition according to claim 1 further comprising a saturated fatty acid (SFA).

### Claim 3 (depends on 1)

The composition according to claim 1 further comprising a vitamin selected from the group consisting of Vitamin A. Vitamin E and gamma-tocopherol.

### Claim 4 (depends on 1)

The composition according to claim 1 wherein the EPA is present in an amount of about 500 mg to about 5000 mg.

### Claim 5 (depends on 1)

The composition according to claim 1 wherein the DHA is present in an amount of about 1000 mg to about 12000 mg.

### Claim 6 (depends on 1)

The composition according to claim 1 wherein the LA is present in an amount of about 1000 mg to about 10600 mg.

### Claim 7 (depends on 1)

The composition according to claim 1 wherein the GLA is present in an amount of about 1000 mg to about 16000 mg.

### Claim 8 (depends on 1)

The composition according to claim 1 further comprising gamma-tocopherol.

### Claim 9 (depends on 8)

The composition according to claim 8 wherein the gamma-tocopherol is present in an amount of about 100 mg to about 3000 mg.

### Claim 10 (depends on 1)

The composition according to claim 1 further comprising beta-carotene.

### Claim 11 (depends on 10)

The composition according to claim 10 wherein the beta-carotene is present in an amount of about 0.1 mg to about 5 mg.

### Claim 12 (depends on 1)

The composition according to claim 1 wherein the monounsaturated fatty acid is selected from the group consisting of 18:1 (oleic acid), 20:1 (eicosenoic acid), 22:1 (docosenoic acid), 24:1 (tetracosenic acid), and mixtures of the foregoing.

### Claim 13 (depends on 1)

The composition according to claim 1 wherein the SFA is selected from the group consisting of 16:0 (palmitic acid) and 18:0 (stearic acid), and mixtures of the foregoing.

### Claim 14 (depends on 1)

The composition according to claim 1 wherein the other omega-3 PUFA, is selected from the group consisting of 18:3 (alpha-linolenic acid), 18:4 (stearidonic acid), 20:4 (eicosatetraenoic acid), and 22:5 (docosapentaenoic acid), and mixture of the foregoing.

### Claim 15 (depends on 14)

The composition of claim 14 wherein the other omega-3 PUPA is present in an amount of about 100 mg to about 2500 mg.

### Claim 16 (depends on 14)

The composition of claim 14 wherein the other omega-3 PUPA is present in an amount of about 300 mg to about 2000 mg.

### Claim 17 (depends on 14)

The composition of claim 14 wherein the other omega-3 PUPA is present in an amount of about 600 mg to about 1000 mg.

### Claim 18 (depends on 1)

The composition of claim 1 wherein the MUFA is present in an amount of about 100 mg to about 3500 mg.

### Claim 19 (depends on 1)

The composition of claim 1 wherein the MUFA is present in an amount of about 750 mg to about 3500 mg.

### Claim 20 (depends on 1)

The composition of claim 1 wherein the MUM is present in an amount of about 1500 mg to about 3500 mg.

### Claim 21 (depends on 13)

The composition of claim 13 wherein the SPA is present in an amount of about 500 mg to about 2000 mg.

### Claim 22

A liquid oral pharmaceutical composition, comprising:
(a) about 1650 mg EPA;
(b) about 4650 mg DHA;
(c) about 3850 mg LA;
(d) about 5850 mg GLA;
(e) about 760 mg gamma-tocopherol, and
(f) about 22 mg Vitamin E.

### Claim 23

A liquid oral pharmaceutical composition, comprising:
a. EPA about 1650 mg/dose
b. DHA about 4650 mg/dose
c. GLA about 2000 mg/dose
d. LA about 3850 mg/dose
e. Other omega-3 PUFAs about 600 mg/dose, comprising:
i. Alpha˜linolenic acid (C18:3n-3) about 37 mg/dose
ii. Stearidonic acid (C18:4n-3) about 73 mg/dose
Eicosatetraenoic acid (C20:4n-3) about 98 mg/dose
iv. Docosapentaenoic acid (C22:5n˜3) about 392 mg/dose
f. MUFAs, comprising:
i. 18:1—about 1300 mg/dose
ii. 20:1—about 250 mg/dose
iii. 22:1—about 82 mg/dose
iv. 24:1—about 82 mg/dose
g. SFAs, comprising:
i. 18:0—about 160 mg/dose
ii. 16:0—about 650 mg/dose
h. Vitamin A about 0.6 mg/dose
i. Vitamin E about 22 mg/dose
j. Gamma-tocopherol about 760 mg/dose

### Claim 24

A method of treating or preventing a neurodegenerative disease in a human subject in need of therapy, comprising administering to the subject an effective amount of a liquid pharmaceutical composition, comprising:
(a) about 500 mg to about 5000 mg EPA;
(b) about 1000 mg to about 12000 mg DHA;
(c) about 1000 mg to about 10600 mg LA; and
(d) about 1000 mg to about 16000 mg GLA.

### Claim 25 (depends on 24)

The method according to claim 24 wherein the composition is administered once daily.

### Claim 26 (depends on 24)

The method according to claim 24 wherein the composition is administered once daily for more than 30 days.

### Claim 27 (depends on 24)

The method according to claim 24 wherein the disease is multiple sclerosis.

### Claim 28 (depends on 24)

The method according to claim 24 wherein the composition comprises:
(a) about 1650 mg EPA;
(b) about 4650 mg DHA;
(e) about 3850 mg LA;
(d) about 5850 mg GLA;
(e) about 760 mg gamma˜tocopherol;
about 22 mg Vitamin E; and
(g) about 0.6 mg beta-carotene.

### Claim 29 (depends on 24)

The method according to claim 24 wherein the composition is administered for more than 60 consecutive days.

### Claim 30 (depends on 24)

The method according to claim 24 wherein the administration results in a decrease in the progression of the disease.
